PR00012

Main study objectives: 1. To evaluate the safety and tolerability of PR00012 in patients with solid tumors who have failed or are intolerant to standard treatment or have no standard treatment. 2. To determine the maximum tolerated dose and recommended dose for the extension phase of PR00012 in patients with solid tumors who have failed or are intolerant to standard treatment or have no standard treatment. 3. To determine the recommended dose for the Phase II clinical study of PR00012. Secondary study objectives: 1. To evaluate the pharmacokinetic characteristics of PR00012 in patients with solid tumors who have failed or are intolerant to standard treatment or have no standard treatment. 2. To evaluate the preliminary anti-tumor activity of PR00012 in patients with solid tumors who have failed or are intolerant to standard treatment or have no standard treatment.